Impressum Bookmark Kontakt Sitemap

Solide Tumoren - Verdauungstrakt - Kolonkarzinom - Weiterführende Informationen

Kolonkarzinom

Leitlinien

 

S3-Leitlinien (2008): www.dgvs.de/media/Leitlinie.pdf

 

ESMO-Konsensus: Ann Oncol 2012 (in print)

 

Studien

 

www.studien.de (DKG); www.eortc.be (EORTC); www.clinicaltrials.gov (NIH/USA)

 

Literatur

 

  • Arkenau HT et al: Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol. 2008; 26: 5910–7

  • Berber E et al: Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol 2005; 23: 1358–64

  • Bokemeyer C et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 10: 663–671

  • Ducreux M et al: Hepatic arterial Oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Fédération Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2005; 23: 4881–7

  • Fairooz K et al: Addition of bevacizumab to bolus fluorouracil and leukovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697–705

  • Folprecht G et al: Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16: 1311–9

  • Folprecht G et al. Tumour response and secondary resectability of colorectal liver metastases followingneoadjuvant   with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38–47

  • Kabbinavar FF et al: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for Pat.s with metastatic colorectal cancer. J Clin Oncol 2005; 23: 3706–12

  • Kelly H et al: Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005; 23: 4553–60

  • Kim M et al.: Quality of life after fast track colorectal surgery. Dtsch Med Wo-chenschr. 2011; 136: 997–1002

  • Köhne CH et al: Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23: 4856–65

  • Köhne CH: How to integrate molecular targeted agents into the continuum of care. ESMO 2011 Educational. Ann Oncol 2010; 21 (suppl 7): vii1–vii6

  • Lang H: Technik der Leberresektion. Chirurg 2007; 78: 761–74

  • Lynch HT et al: Molecular screening for the Lynch Syndrome – better than family history? N Engl J Med 2005; 352: 1920–2

  • Marcello P W: Single incision laparoscopic colectomy: boutique surgery or the new standard? Dis Colon Rectum. 2011; 54: 660–1

  • Petrelli NJ et al: Hepatic resection: the last surgical frontier for colorectal cancer. J Clin Oncol 2005; 23: 4475–7

  • Popat S et al: Systematic review of microsatellite instability an colorectal cancer prognosis. J Clin Oncol 2005; 23: 609–18

  • Raju R et al: Chemoprevention of colorectal cancer. Dis Colon Rectum 2006; 49: 113–24

  • Stippel D: Percutaneous, laparoscopic and open surgical radiofrequency ablation of malignant liver lesions. Zentralbl Chir 2007; 132: 293–9

  • Twelves C et al: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696–704

  • Van Cutsem E et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408–17